Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,367,397
  • Shares Outstanding, K 191,537
  • Annual Sales, $ 2,160 K
  • Annual Income, $ -273,840 K
  • 60-Month Beta 2.13
  • Price/Sales 1,131.81
  • Price/Cash Flow N/A
  • Price/Book 13.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.12
  • Low Estimate -0.47
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -2.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.59 +12.60%
on 06/03/19
16.05 -18.69%
on 05/21/19
-2.56 (-16.40%)
since 05/17/19
3-Month
11.59 +12.60%
on 06/03/19
19.51 -33.11%
on 04/01/19
-5.51 (-29.69%)
since 03/15/19
52-Week
11.55 +12.99%
on 01/18/19
27.33 -52.25%
on 07/18/18
-10.42 (-44.40%)
since 06/15/18

Most Recent Stories

More News
Immunomedics to Participate in Upcoming Healthcare Conferences

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate...

IMMU : 13.05 (+5.58%)
Interesting IMMU Put And Call Options For July 19th

Investors in Immunomedics, Inc. saw new options become available this week, for the July 19th expiration.

IMMU : 13.05 (+5.58%)
Immunomedics: 1Q Earnings Snapshot

MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Thursday reported a loss of $87.3 million in its first quarter.

IMMU : 13.05 (+5.58%)
Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update

Agreement with Janssen Established to Co-Promote Balversa

IMMU : 13.05 (+5.58%)
Immunomedics To Participate In Upcoming Healthcare Conferences

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate...

IMMU : 13.05 (+5.58%)
June 14th Options Now Available For Immunomedics (IMMU)

Investors in Immunomedics, Inc. saw new options begin trading today, for the June 14th expiration.

IMMU : 13.05 (+5.58%)
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call...

IMMU : 13.05 (+5.58%)
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop and Commercialize Sacituzumab Govitecan for All Cancer Indications in Greater China,...

IMMU : 13.05 (+5.58%)
Immunomedics Announces Departure of Chief Medical Officer

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Rob Iannone, M.D., has decided...

IMMU : 13.05 (+5.58%)
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark

Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

PDLI : 2.99 (+2.75%)
SGEN : 71.61 (+4.54%)
IMMU : 13.05 (+5.58%)
TAK : 17.07 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade IMMU with:

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

2nd Resistance Point 13.68
1st Resistance Point 13.37
Last Price 13.05
1st Support Level 12.55
2nd Support Level 12.05

See More

52-Week High 27.33
Fibonacci 61.8% 21.30
Fibonacci 50% 19.44
Fibonacci 38.2% 17.58
Last Price 13.05
52-Week Low 11.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar